What do Hector Gomez,Lonnie Bookbinder,and Richard Gabriel have in common ?
News Release
07 November 2002
Contact: Mark S. DiSalvo
978 794-3366 X 322
mdisalvo@sema4usa.com
Semaphore Dedicates Life Sciences Diligence Practice
Firm emphasizes and expands Technology and Sciences diligence to Bio/Pharma markets.
(Boston- London- Zurich) Sema4, Inc. (Semaphore) announces the expansion of its Technology Diligence practice. Stating that Semaphore clients are experiencing greater activity in the Life Sciences markets, Semaphore CEO Mark S. DiSalvo states “We thought it appropriate to greater emphasize the skills and resources we have to provide assurance and Independent Verification and Validation in the Life Sciences and Bio/Pharma markets, especially since our clients are asking us to perform this level of assurance.”
This dedicated Life Sciences business practice was created to provide visibility and clarity to the decision-making process. “It facilitates informed judgments on risk and opportunity. The Life Sciences are often subject to misunderstanding, misapplication and misrepresentation,” said DiSalvo. DiSalvo explained that this confusion has a deleterious effect on productivity in even the most business savvy environments. Semaphore research has discovered that when Technology Diligence is applied prior to, or in concert with, a funding event it provides appropriate and necessary discipline to the judgment process. The result allows for increased confidence in the decision contemplated and executed. Research confirms that Bio/Pharma projects such as drug development are nearly always over budget, behind schedule, or are abandoned completely. Facts are that the FDA approves less than 2% of the drug pipeline. Those that do receive approval often are not commercially successful. Semaphore services in this space include Clinical Trial review, FDA compliance and certification process monitoring, proof of science concept, and acquisition target validation.
The firm has significantly expanded its resources globally in the Life Sciences space. Richard Gabriel former CEO of Calix Corporation is the point person for the firm as head of Life Sciences diligence services practice. “I am delighted to join the quality team represented by Semaphore. Its skills providing real-world diligence from Emerging Technologies to Enterprise Software to Life Sciences are legendary,” he added. His team includes: Hector Gomez, MD, Ph.D, former CEO of Transcend Therapeutics, Inc. and Lonnie Bookbinder, Ph.D, an experienced large Pharma executive. “The strength of this dedicated team will offer our clients the clearest direction and best assurance of success possible. We bring hard science and business savvy to the table every day,” Gabriel added.
About Semaphore Services:
Semaphore provides Technology Diligence, Project Assurance and Business Advisory services in areas from Enterprise Software to Life Sciences for Corporations, Boards of Directors, and Private Equity, VC, Law firms and Investment Banks. Semaphore is a 14-year consultancy providing skilled real-world practitioner Technology Diligence, Project Assurance and Business Advisory services. Among its offerings are warranted Technology Diligence to the funding community, Independent Verification and Validation for ongoing projects, asset valuation, licensing evaluation and marketing and sales analysis. Clients include: Travelers Insurance, Shared Medical Systems, Fleet Bank, Sandia National Labs, Vertex Pharmaceutical, The Federal Reserve System, Zurich Allied, Alta Communications, M/C Venture Partners, IDX, and the National Security Agency.
About Semaphore Services: www.sema4usa.com or www.sema4europe.com:
-30-
•back to previous page
/ home / about us / services / hot jobs / glossary / contact us /
© 2003 semaphore. webmaster
